Cidara Therapeutics (CDTX) News Today $93.12 -3.04 (-3.16%) Closing price 10/24/2025 04:00 PM EasternExtended Trading$93.36 +0.24 (+0.26%) As of 10/24/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock CDTX Latest News All Sources Trusted Sources MarketBeat Barchart Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent October 2025 September 2025 August 2025 July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 Time Period Cidara Therapeutics (NASDAQ:CDTX) Receives Sell (D-) Rating from Weiss Ratings2 hours ago | marketbeat.comCidara Therapeutics announces presentation on CD388 at ESWI ConferenceOctober 25 at 3:31 AM | msn.comWest Michigan Advisors LLC Purchases 3,000 Shares of Cidara Therapeutics, Inc. $CDTXOctober 24 at 9:42 AM | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Stock Crosses Above Fifty Day Moving Average - Here's WhyOctober 24 at 5:30 AM | marketbeat.comCidara Therapeutics' (CDTX) "Buy" Rating Reiterated at HC WainwrightOctober 24 at 3:00 AM | americanbankingnews.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Recommendation of "Moderate Buy" from AnalystsOctober 24 at 2:25 AM | americanbankingnews.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Rating of "Moderate Buy" from AnalystsOctober 24 at 2:23 AM | marketbeat.comH.C. Wainwright reiterates Cidara as top pick after influenza dataOctober 24 at 2:05 AM | msn.comCidara Therapeutics to Report Third Quarter 2025 Financial Results and Host Quarterly Conference Call on November 6, 2025October 23 at 4:05 PM | globenewswire.comCidara Therapeutics Announces Late-Breaking Presentation on CD388 at 10ᵗʰ ESWI Influenza Conference 2025October 23 at 8:00 AM | globenewswire.comCidara Therapeutics: A Potential Blockbuster In Flu PreventionOctober 21, 2025 | seekingalpha.comCidara Therapeutics (NASDAQ:CDTX) Given "Buy" Rating at HC WainwrightOctober 21, 2025 | marketbeat.comCidara Therapeutics Announces Late-Breaking Phase 2b Data Presentation on CD388 at ID Week 2025October 21, 2025 | globenewswire.comMorgan Stanley Initiates Cidara Therapeutics (CDTX) With a BuyOctober 19, 2025 | msn.comCidara Therapeutics (NASDAQ:CDTX) Research Coverage Started at Morgan StanleyOctober 19, 2025 | americanbankingnews.comFDA Grants Cidara Therapeutics’ CD388 Breakthrough Therapy Designation for Flu Prevention in High-Risk PatientsOctober 16, 2025 | msn.comMorgan Stanley Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight RecommendationOctober 16, 2025 | msn.comCidara Therapeutics initiated with an Overweight at Morgan StanleyOctober 16, 2025 | msn.comMorgan Stanley Begins Coverage on Cidara Therapeutics (NASDAQ:CDTX)October 16, 2025 | marketbeat.comAberdeen Group plc Has $12.66 Million Stock Position in Cidara Therapeutics, Inc. $CDTXOctober 16, 2025 | marketbeat.comCidara Therapeutics to Present Late-Breaking Phase 2 Data on CD388 for Influenza at ID Week 2025October 13, 2025 | quiverquant.comQCidara Therapeutics to Present Late-Breaking Clinical Phase 2 Data on CD388 at ID Week 2025October 13, 2025 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Shares Gap Up on Analyst UpgradeOctober 11, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Now Covered by JPMorgan Chase & Co.October 11, 2025 | marketbeat.comJP Morgan Initiates Coverage of Cidara Therapeutics (CDTX) with Overweight RecommendationOctober 10, 2025 | msn.comWhy Cidara Therapeutics (CDTX) Is Up 12.4% After Breakthrough Therapy Status for Novel Flu Drug CD388October 10, 2025 | finance.yahoo.comWBB Securities Issues Positive Forecast for Cidara Therapeutics (NASDAQ:CDTX) Stock PriceOctober 10, 2025 | marketbeat.comHC Wainwright & Co. Maintains Cidara Therapeutics (CDTX) Buy RecommendationOctober 10, 2025 | msn.comCidara Therapeutics (NASDAQ:CDTX) Hits New 12-Month High Following Analyst UpgradeOctober 10, 2025 | marketbeat.comCidara Therapeutics (NASDAQ:CDTX) Price Target Raised to $150.00October 10, 2025 | marketbeat.comCidara Therapeutics to Present at 10th ESWI Influenza Conference 2025October 10, 2025 | globenewswire.comCidara Therapeutics' (CDTX) "Sell (D-)" Rating Reaffirmed at Weiss RatingsOctober 9, 2025 | marketbeat.comCidara Therapeutics Granted FDA Breakthrough Therapy Designation For Flu-Preventing AntiviralOctober 9, 2025 | msn.comCidara Therapeutics Receives U.S. FDA Breakthrough Therapy Designation for CD388 in Seasonal Influenza PreventionOctober 9, 2025 | globenewswire.comCidara Therapeutics (NASDAQ:CDTX) Shares Up 5.5% - Time to Buy?October 7, 2025 | marketbeat.comJMP Securities Maintains Cidara Therapeutics (CDTX) Market Outperform RecommendationOctober 4, 2025 | msn.comCidara Therapeutics (CDTX): Assessing Valuation as Phase 3 Trial for Influenza Preventative Expands to Broader Patient GroupsOctober 2, 2025 | finance.yahoo.comCidara Therapeutics Announces BARDA Award to Support Expanded Manufacturing and Clinical Development of CD388, its Non-Vaccine Influenza Preventative TherapeuticOctober 2, 2025 | globenewswire.comCidara Therapeutics (CDTX) Price Target Increased by 77.93% to 134.30September 30, 2025 | msn.comCidara Therapeutics, Inc. (CDTX) Accelerates Phase 3 Trial for Single-Dose Flu Antiviral CD388September 30, 2025 | finance.yahoo.comCidara Therapeutics (NASDAQ:CDTX) Sets New 12-Month High - Should You Buy?September 30, 2025 | marketbeat.comCidara Therapeutics, Inc. (NASDAQ:CDTX) Receives Consensus Rating of "Buy" from BrokeragesSeptember 29, 2025 | marketbeat.comWhy Cidara Therapeutics Was Such a Healthy Stock TodaySeptember 26, 2025 | fool.comCidara Therapeutics (NASDAQ:CDTX) Stock Price Up 5.9% Following Analyst UpgradeSeptember 26, 2025 | marketbeat.comHC Wainwright Forecasts Strong Price Appreciation for Cidara Therapeutics (NASDAQ:CDTX) StockSeptember 26, 2025 | marketbeat.comGuggenheim Maintains Cidara Therapeutics (CDTX) Buy RecommendationSeptember 26, 2025 | msn.comCidara Therapeutics Announces First Participants Dosed in Phase 3 ANCHOR Trial Evaluating CD388 for the Prevention of Seasonal Influenza in High-Risk PopulationsSeptember 25, 2025 | globenewswire.comCidara Therapeutics Expands Phase 3 Trial for CD388September 25, 2025 | msn.comCidara stock soars after FDA feedback on expanded Phase 3 trialSeptember 25, 2025 | investing.comCidara jumps after expedited late-stage trial plan for flu therapySeptember 25, 2025 | msn.com Get Cidara Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CDTX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CDTX Media Mentions By Week CDTX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CDTX News Sentiment▼0.430.93▲Average Medical News Sentiment CDTX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CDTX Articles This Week▼175▲CDTX Articles Average Week Get the Latest News and Ratings for CDTX and Related Stocks Enter your email address to receive the latest news and analysts' ratings for Cidara Therapeutics and its competitors. Sign Up View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. Related Companies and Tools Related Companies Moderna News Today Revolution Medicines News Today Verona Pharma PLC American Depositary Share News Today Rhythm Pharmaceuticals News Today Abivax News Today Merus News Today Cytokinetics News Today Avidity Biosciences News Today Nuvalent News Today Grifols News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CDTX) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredFront-Run Buffett's Shocking Gold MoveA Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cidara Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cidara Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
